CCCCC4 Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of C4 Therapeutics, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CCCC본 종목 | $424M#4 | — | 1.7x#5 | 11.8x#4 | 1.0%#4 | 0.3%#4 | -320.5%#4 | -42.5%#4 | — | — | 1.3%#3 | — |
| TECX | $544M#1 | — | 2.4x#6 | — | — | -27.9%#7 | — | -33125.9%#7 | -713.5%#2 | — | 73.5%#2 | — |
| RGNX | $527M#2 | — | 7.3x#7 | 3.1x#2 | 104.5%#2 | 14.6%#3 | -94.6%#2 | -270.2%#6 | — | — | -13.9%#4 | — |
| DNA | $450M#3 | — | 1.1x#1 | 2.6x#1 | -25.1%#5 | 42.8%#2 | -185.3%#3 | -0.1%#1 | — | — | -33.5%#5 | — |
| ARTV | $420M#5 | — | 1.2x#2 | — | -100.0%#6 | -28.3%#8 | — | -24.1%#3 | — | — | 262.7%#1 | — |
| LXEO | $342M#7 | — | 1.5x#3 | 523.1x#6 | — | -1.7%#5 | -16706.0%#6 | -42.5%#5 | — | — | — | — |
| IPSC | $340M#8 | — | 1.5x#4 | 3.1x#3 | 1556.8%#1 | 92.4%#1 | -15.8%#1 | -4.1%#2 | -9.3%#1 | — | — | — |
| OCGN | $344M#6 | — | — | 78.0x#5 | 8.8%#3 | -25.9%#6 | -1425.7%#5 | — | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice